研究园简易版
·
经典书籍
·
期刊文章
·
有原文
·
完整版(可多选筛选、搜索)
·
首页
搜索
2022 年 · Clinical Trials(临床试验)
138 篇,新的在前。点标题看作者和摘要。
回到 2022 年
Optimization of the two‐stage group sequential three‐arm gold‐standard design for non‐inferiority trials
· SiM · 2022-12-28 · 在第 1 页
Estimating the distribution of ratio of paired event times in phase II oncology trials
· SiM · 2022-12-27 · 在第 1 页
Power analyses for stepped wedge designs with multivariate continuous outcomes
· SiM · 2022-12-24 · 在第 1 页
Bayesian Sample Size Calculations for Comparing Two Strategies in SMART Studies
· Biometrics · 2022-12-13 · 在第 1 页
A connection between survival multistate models and causal inference for external treatment interruptions
· SMMR · 2022-12-04 · 在第 2 页
The population-wise error rate for clinical trials with overlapping populations
· SMMR · 2022-12-01 · 在第 2 页
Point estimation for adaptive trial designs I: A methodological review
· SiM · 2022-11-30 · 在第 2 页
Design Considerations for Two-Stage Enrichment Clinical Trials
· Biometrics · 2022-11-27 · 在第 3 页
Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial
· SiM · 2022-11-25 · 在第 3 页
Assessing Exposure-Time Treatment Effect Heterogeneity in Stepped-Wedge Cluster Randomized Trials
· Biometrics · 2022-11-23 · 在第 3 页
Adjusting for treatment selection in phase II/III clinical trials with time to event data
· SiM · 2022-11-23 · 在第 3 页
Simulating time-to-event data subject to competing risks and clustering: A review and synthesis
· SMMR · 2022-11-22 · 在第 3 页
Target estimands for population‐adjusted indirect comparisons
· SiM · 2022-11-17 · 在第 3 页
Some considerations on target estimands for health technology assessment
· SiM · 2022-11-17 · 在第 3 页
Point estimation following a two-stage group sequential trial
· SMMR · 2022-11-16 · 在第 4 页
Sensitivity analyses in longitudinal clinical trials via distributional imputation
· SMMR · 2022-11-06 · 在第 4 页
Contrasting Principal Stratum and Hypothetical Strategy Estimands in Multi-Period Crossover Trials with Incomplete Data
· Biometrics · 2022-10-29 · 在第 5 页
Sample size determination for the association between longitudinal and time‐to‐event outcomes using the joint modeling time‐dependent slopes parameterization
· SiM · 2022-10-28 · 在第 5 页
Statistical Inference and Power Analysis for Direct and Spillover Effects in Two-Stage Randomized Experiments
· Biometrics · 2022-10-25 · 在第 5 页
Multi-arm covariate adjusted response adaptive designs for ordinal outcome clinical trials
· SMMR · 2022-10-20 · 在第 5 页
Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression
· SiM · 2022-10-19 · 在第 5 页
Dose finding studies for therapies with late‐onset toxicities: A comparison study of designs
· SiM · 2022-10-17 · 在第 5 页
A general method for calculating power for GEE analysis of complete and incomplete stepped wedge cluster randomized trials
· SMMR · 2022-10-17 · 在第 5 页
Shotgun-2: A Bayesian phase I/II basket trial design to identify indication-specific optimal biological doses
· SMMR · 2022-10-11 · 在第 5 页
A proper statistical inference framework to compare clinical trial and real‐world progression‐free survival data
· SiM · 2022-10-05 · 在第 6 页
Online control of the False Discovery Rate in group-sequential platform trials
· SMMR · 2022-10-03 · 在第 6 页
Bayesian local exchangeability design for phase II basket trials
· SiM · 2022-09-30 · 在第 7 页
Blinded sample size re‐estimation for comparing over‐dispersed count data incorporating follow‐up lengths
· SiM · 2022-09-23 · 在第 7 页
Regression analysis for covariate‐adaptive randomization: A robust and efficient inference perspective
· SiM · 2022-09-22 · 在第 7 页
Nonparametric Estimation of Repeated Densities with Heterogeneous Sample Sizes
· JASA · 2022-09-20 · 在第 7 页
Group sequential methods for interim monitoring of randomized clinical trials with time‐lagged outcome
· SiM · 2022-09-18 · 在第 8 页
Bounded-width confidence interval following optimal sequential analysis of adverse events with binary data
· SMMR · 2022-09-18 · 在第 8 页
Estimation of the treatment effect following a clinical trial that stopped early for benefit
· SMMR · 2022-09-06 · 在第 8 页
Bias correction based on weighted likelihood for conditional estimation of subgroup effects in randomized clinical trials
· SiM · 2022-09-02 · 在第 8 页
Optimal sampling allocation for outcome-dependent designs in cluster-correlated data settings
· SMMR · 2022-08-30 · 在第 8 页
Approximate Bayesian computation design for phase I clinical trials
· SMMR · 2022-08-29 · 在第 8 页
Joint Inference for Competing Risks Data Using Multiple Endpoints
· Biometrics · 2022-08-26 · 在第 9 页
Synthesizing studies for comparing different treatment sequences in clinical trials
· SiM · 2022-08-25 · 在第 9 页
Noninferiority testing with censoring when the event rate is low
· SiM · 2022-08-22 · 在第 9 页
Single‐stage, three‐arm, adaptive test strategies for non‐inferiority trials with an unstable reference
· SiM · 2022-08-18 · 在第 9 页
Comparison of treatments with ordinal responses in trials with sequential monitoring and response‐adaptive randomization
· SiM · 2022-08-16 · 在第 9 页
Communication‐efficient estimation and inference for high‐dimensional quantile regression based on smoothed decorrelated score
· SiM · 2022-08-13 · 在第 9 页
Design and analysis of cluster randomized trials with time‐to‐event outcomes under the additive hazards mixed model
· SiM · 2022-07-31 · 在第 10 页
Optimal Multiple Testing and Design in Clinical Trials
· Biometrics · 2022-07-27 · 在第 10 页
Seconder of the Vote of thanks to Vansteelandt and Dukes and Contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’
· JRSSB · 2022-07-26 · 在第 11 页
Rachael V. Phillips and Mark J. van der Laan’s Contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
Proposer of the Vote of Thanks and Contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
Pallavi Basuʼs Contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
Niwen Zhou and Xu Guo’s Contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
Michael Lavine and James Hodges’ Contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
Mats J Stensrud and Aaron L. Sarvet’s Contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
Kuldeep Kumar’s Contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
Ilya Shpitser’s Contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
Christian Hennig's contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
Authors' reply to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
Assumption-lean Inference for Generalised Linear Model Parameters
· JRSSB · 2022-07-26 · 在第 11 页
Anna Choi and Weng Kee Wong’s Contribution to the Discussion of ‘Assumption-Lean Inference for Generalised Linear Model Parameters’ by Vansteelandt and Dukes
· JRSSB · 2022-07-26 · 在第 11 页
The benefits of covariate adjustment for adaptive multi-arm designs
· SMMR · 2022-07-25 · 在第 11 页
Sample size methods for evaluation of predictive biomarkers
· SiM · 2022-07-20 · 在第 11 页
Optimal single-arm two-stage designs with consideration of dependency on efficacy and safety
· SMMR · 2022-07-15 · 在第 12 页
Bootstrap vs asymptotic variance estimation when using propensity score weighting with continuous and binary outcomes
· SiM · 2022-07-15 · 在第 12 页
Designing a longitudinal clinical trial based on a composite endpoint: Sample size, monitoring, and adaptation
· SiM · 2022-07-11 · 在第 12 页
Adaptive response‐dependent two‐phase designs: Some results on robustness and efficiency
· SiM · 2022-07-07 · 在第 13 页
Analysis of stepped wedge cluster randomized trials in the presence of a time‐varying treatment effect
· SiM · 2022-06-30 · 在第 13 页
Pair-Switching Rerandomization
· Biometrics · 2022-06-27 · 在第 13 页
Estimands for factorial trials
· SiM · 2022-06-25 · 在第 13 页
Model‐based Bayesian inference under computer assisted balance‐improving designs
· SiM · 2022-06-24 · 在第 13 页
Nonparametric Inference of General While-Alive Estimands for Recurrent Events
· Biometrics · 2022-06-22 · 在第 13 页
Using principal stratification in analysis of clinical trials
· SiM · 2022-06-13 · 在第 14 页
Group sequential methods for the Mann-Whitney parameter
· SMMR · 2022-06-13 · 在第 14 页
Sample size calculation for randomized selection trials with a time‐to‐event endpoint and a margin of practical equivalence
· SiM · 2022-06-10 · 在第 14 页
Extending the Continual Reassessment Method to accommodate step‐up dosing in Phase I trials
· SiM · 2022-06-05 · 在第 14 页
A straightforward meta‐analysis approach for oncology phase I dose‐finding studies
· SiM · 2022-06-05 · 在第 14 页
Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trials
· SMMR · 2022-05-31 · 在第 15 页
The batched stepped wedge design: A design robust to delays in cluster recruitment
· SiM · 2022-05-21 · 在第 16 页
Real time monitoring and prediction of time to endpoint maturation in clinical trials
· SiM · 2022-05-19 · 在第 16 页
Translating questions to estimands in randomized clinical trials with intercurrent events
· SiM · 2022-05-16 · 在第 16 页
Bayesian model of disease progression in mucopolysaccaridosis IIIA
· SiM · 2022-05-13 · 在第 16 页
A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints
· Biometrics · 2022-05-12 · 在第 16 页
An objective Bayesian approach to estimation in multistage experiments
· SMMR · 2022-05-11 · 在第 17 页
Power Analysis for Cluster Randomized Trials with Continuous Coprimary Endpoints
· Biometrics · 2022-05-09 · 在第 17 页
Nonparametric Estimation of the Causal Effect of a Stochastic Threshold-Based Intervention
· Biometrics · 2022-05-08 · 在第 17 页
Exact-Corrected Confidence Interval for Risk Difference in Noninferiority Binomial Trials
· Biometrics · 2022-05-08 · 在第 17 页
Calculating power for the Finkelstein and Schoenfeld test statistic for a composite endpoint with two components
· SiM · 2022-04-29 · 在第 17 页
Response-adaptive treatment randomization for multiple comparisons of treatments with recurrent event responses
· SMMR · 2022-04-28 · 在第 17 页
A Bayesian Model with Application for Adaptive Platform Trials Having Temporal Changes
· Biometrics · 2022-04-27 · 在第 17 页
Design and analysis of partially randomized preference trials with propensity score stratification
· SMMR · 2022-04-26 · 在第 17 页
Combining individual patient data from randomized and non-randomized studies to predict real-world effectiveness of interventions
· SMMR · 2022-04-26 · 在第 17 页
Statistical power and sample size requirements to detect an intervention by time interaction in four‐level longitudinal cluster randomized trials
· SiM · 2022-04-19 · 在第 18 页
Subgroup‐specific dose finding for phase I‐II trials using Bayesian clustering
· SiM · 2022-04-16 · 在第 18 页
Re-randomisation trials in multi-episode settings: Estimands and independence estimators
· SMMR · 2022-04-14 · 在第 18 页
Efficiency of a randomized confirmatory basket trial design constrained to control the family wise error rate by indication
· SMMR · 2022-04-11 · 在第 18 页
Bayesian sample size determination for diagnostic accuracy studies
· SiM · 2022-04-10 · 在第 18 页
How large should the next study be? Predictive power and sample size requirements for replication studies
· SiM · 2022-04-08 · 在第 18 页
Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated
· SiM · 2022-04-08 · 在第 18 页
An Alternative Metric for Evaluating the Potential Patient Benefit of Response-Adaptive Randomization Procedures
· Biometrics · 2022-04-08 · 在第 18 页
Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials
· SMMR · 2022-04-05 · 在第 18 页
Limitations of clinical trial sample size estimate by subtraction of two measurements
· SiM · 2022-03-30 · 在第 19 页
Inclusion of unexposed clusters improves the precision of fixed effects analysis of stepped‐wedge cluster randomized trials
· SiM · 2022-03-29 · 在第 20 页
A generalized weighted combination test of treatment effect for clinical trials with a sequential parallel comparison design and binary endpoint
· SiM · 2022-03-28 · 在第 20 页
Toward Better Practice of Covariate Adjustment in Analyzing Randomized Clinical Trials
· JASA · 2022-03-27 · 在第 20 页
Adaptive enrichment designs with a continuous biomarker
· Biometrics · 2022-03-25 · 在第 20 页
Sample size calculation for the augmented logrank test in randomized clinical trials
· SiM · 2022-03-23 · 在第 20 页
A comparison of analytical strategies for cluster randomized trials with survival outcomes in the presence of competing risks
· SMMR · 2022-03-15 · 在第 21 页
Cross-Trait Prediction Accuracy of Summary Statistics in Genome-Wide Association Studies
· Biometrics · 2022-03-12 · 在第 21 页
Sensitivity analysis for unmeasured confounding in the estimation of marginal causal effects
· Biometrika · 2022-03-11 · 在第 21 页
Group sequential design for randomized trials using “first hitting time” model
· SiM · 2022-03-10 · 在第 21 页
The required size of cluster randomized trials of nonpharmaceutical interventions in epidemic settings
· SiM · 2022-03-07 · 在第 21 页
Model‐assisted analyses of longitudinal, ordinal outcomes with absorbing states
· SiM · 2022-03-07 · 在第 21 页
Bayesian Sample Size Determination Using Commensurate Priors to Leverage Preexperimental Data
· Biometrics · 2022-03-06 · 在第 22 页
CFO: Calibration-free odds design for phase I/II clinical trials
· SMMR · 2022-03-03 · 在第 22 页
Sample size estimation using a latent variable model for mixed outcome co‐primary, multiple primary and composite endpoints
· SiM · 2022-02-23 · 在第 22 页
Commentary on training and education in medical statistics, in celebration of 40 years of statistics in medicine and 50 years of the MSc medical statistics at LSHTM
· SiM · 2022-02-23 · 在第 22 页
A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy
· SMMR · 2022-02-22 · 在第 22 页
Multi-scale Fisher’s independence test for multivariate dependence
· Biometrika · 2022-02-21 · 在第 22 页
Estimation of the proportion of treatment effect explained by a high‐dimensional surrogate
· SiM · 2022-02-21 · 在第 22 页
Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison design
· SiM · 2022-02-20 · 在第 22 页
Common scale minimal sufficient balance: An improved method for covariate‐adaptive randomization based on the Wilcoxon‐Mann‐Whitney odds ratio statistic
· SiM · 2022-02-17 · 在第 23 页
Bayesian two‐stage design for phase II oncology trials with binary endpoint
· SiM · 2022-02-17 · 在第 23 页
Optimal adaptive promising zone designs
· SiM · 2022-02-14 · 在第 23 页
Constrained randomization and statistical inference for multi‐arm parallel cluster randomized controlled trials
· SiM · 2022-02-10 · 在第 23 页
Sample size calculation for cluster randomized trials with zero‐inflated count outcomes
· SiM · 2022-02-09 · 在第 23 页
Model misspecification in stepped wedge trials: Random effects for time or treatment
· SiM · 2022-02-08 · 在第 23 页
Robustness of κ‐type coefficients for clinical agreement
· SiM · 2022-02-06 · 在第 23 页
Bayesian set of best dynamic treatment regimes: Construction and sample size calculation for SMARTs with binary outcomes
· SiM · 2022-02-06 · 在第 23 页
TITE‐BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late‐onset toxicity and efficacy
· SiM · 2022-01-31 · 在第 24 页
Sensitivity to missing not at random dropout in clinical trials: Use and interpretation of the trimmed means estimator
· SiM · 2022-01-31 · 在第 25 页
A comparison of estimation methods adjusting for selection bias in adaptive enrichment designs with time‐to‐event endpoints
· SiM · 2022-01-31 · 在第 25 页
Sample size formula for a win ratio endpoint
· SiM · 2022-01-27 · 在第 25 页
Sequential modeling for a class of reference‐based imputation methods in clinical trials with quantitative or binary outcomes
· SiM · 2022-01-25 · 在第 25 页
A nonparametric Bayesian method for dose finding in drug combinations cancer trials
· SiM · 2022-01-25 · 在第 25 页
Response adaptive intervention allocation in stepped‐wedge cluster randomized trials
· SiM · 2022-01-21 · 在第 25 页
An order restricted multi‐arm multi‐stage clinical trial design
· SiM · 2022-01-19 · 在第 26 页
Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials
· SiM · 2022-01-13 · 在第 26 页
Power analysis for stepped wedge trials with multiple interventions
· SiM · 2022-01-11 · 在第 26 页
Sample size calculation in hierarchical 2×2 factorial trials with unequal cluster sizes
· SiM · 2022-01-02 · 在第 27 页
Under-bagging Nearest Neighbors for Imbalanced Classification
· JMLR · 2022 · 在第 27 页
Posterior Asymptotics for Boosted Hierarchical Dirichlet Process Mixtures
· JMLR · 2022 · 在第 30 页